It’s Time for the F.D.A. to Fully Approve the mRNA Vaccines

Here’s a paradox: A new drug for Alzheimer’s disease, aducanumab, gets approved by the Food and Drug Administration through an accelerated process without sufficient data, although there…

Eric TopolJuly 1, 2021